Lack of association between first myocardial infarction and past use of erythromycin, tetracycline, or doxycycline

Emerging Infectious Diseases

Volumn 5, Issue 2, 1999, Pages 281-284

  Jackson, Lisa A ^a,b   Smith, Nicholas L ^a   Heckbert, Susan R ^a   Grayston, J Thomas ^a   Siscovick, David S ^a   Psaty, Bruce M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; ERYTHROMYCIN; TETRACYCLINE;

ADULT; AGED; ARTICLE; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; DISEASE ASSOCIATION; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; RISK ASSESSMENT;

EID: 0032901883     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid0502.990216     Document Type: Article

References (13)

1. Saikku P, Leinonen M, Tenkanen L, Linnanmaki E, Ekman MR, Manninen V, et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med 1992;116:273-8.
2. Campbell LA, O'Brien ER, Cappuccio AL, Kuo CC, Wang SP, Stewart D, et al. Detection of Chlamydia pneumoniae (TWAR) in human coronary atherectomy tissues. J Infect Dis 1995;172:585-8.
3. Jackson LA, Campbell LA, Kuo CC, Rodriguez DI, Grayston JT. Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen. J Infect Dis 1997;176:292.
4. Muhlestein JB, Anderson JL, Hammond EH, Zhao L, Trehane S, Schwobe EP, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998;97:633-6.
5. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997;96:404-7.
6. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. Lancet 1997;350:404-7.
7. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620-5.
8. Psaty BM, Heckbert SR, Atkins D, Lemaitre R, Koepsell TD, Wahl PW, et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med 1994;154:1333-9.
9. Heckbert SR, Weiss NS, Koepsell TD, Lemaitre RN, Smith NL, Siscovick DS, et al. Duration of estrogen replacement therapy in relation to the risk of incident myocardial infarction in postmenopausal women. Arch Intern Med 1997;157:1330-6.
10. Dunn CJ, Barradell LB. Azithromycin. A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections. Drugs 1996;51:483-505.
11. Markham A, Faulds D. Roxithromycin. An update of its antimicrobial activity, pharmacokinetic properties and therapeutic use. Drugs 1994;48:297-326.
12. Anderson R, Theron AJ, Feldman C. Membrane-stabilizing, anti-inflammatory interactions of macrolides with human neutrophils. Inflammation 1996;20:693-705.
13. Martin D, Bursill J, Qui MR, Breit SN, Campbell T. Alternative hypothesis for efficacy of macrolides in acute coronary syndromes. Lancet 1998;351:1858-9.